UNSPSC 51312002: Ebastine

This classification denotes a histamine-1 receptor antagonist with the molecular formula C32H39NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TQD7Q784P1, chemically known as 1-butanone, 1-(4-(1,1-dimethylethyl)phenyl)-4-(4-(diphenylmethoxy)-1-piperidinyl)- but generally known as ebastine, which bears US NIH Compound Identifier 3191. European Medicines Agency schedules Ebastine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06435MIG.

UNSPSC 51312002 Ebastine, a Commodity code, does not reflect the pharmaceutical procurement activity actually being solicited by state and local governments under this designation. Recent opportunities tagged to this code center on naloxone procurement, direct-to-manufacturer pharmacy programs, and generic multi-source pharmaceutical distribution — none of which involve ebastine, an antihistamine. The mismatch between code name and actual scope signals potential misclassification in the source data rather than genuine ebastine demand.

The three recent opportunities show state and county health agencies, cooperative purchasing alliances, and state human services commissions executing pharmaceutical procurement across Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, response due July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products through authorized wholesalers, with responses due March 26, 2026 and contract effective July 1, 2026. Because the code shows no recent activity genuinely aligned with ebastine supply, assess pursuit based on whether your firm participates in broader pharmaceutical distribution, naloxone emergency response programs, or state pharmacy benefit initiatives rather than ebastine-specific demand.